NZ588435A - Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer) - Google Patents

Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)

Info

Publication number
NZ588435A
NZ588435A NZ588435A NZ58843509A NZ588435A NZ 588435 A NZ588435 A NZ 588435A NZ 588435 A NZ588435 A NZ 588435A NZ 58843509 A NZ58843509 A NZ 58843509A NZ 588435 A NZ588435 A NZ 588435A
Authority
NZ
New Zealand
Prior art keywords
ace2
exception
lung cancer
angiotensin
converting enzyme
Prior art date
Application number
NZ588435A
Other languages
English (en)
Inventor
Evelyne Janzek-Hawlat
Hans Loibner
Manfred Schuster
Bernhard Peball
Original Assignee
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag
Publication of NZ588435A publication Critical patent/NZ588435A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ588435A 2008-04-09 2009-04-07 Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer) NZ588435A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0056608A AT506632A1 (de) 2008-04-09 2008-04-09 Behandlung von tumorerkrankungen
PCT/AT2009/000136 WO2009124330A2 (de) 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen

Publications (1)

Publication Number Publication Date
NZ588435A true NZ588435A (en) 2012-10-26

Family

ID=41130316

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ588435A NZ588435A (en) 2008-04-09 2009-04-07 Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)

Country Status (12)

Country Link
US (1) US8946162B2 (enExample)
EP (2) EP2274005B1 (enExample)
JP (1) JP5650639B2 (enExample)
AT (1) AT506632A1 (enExample)
AU (1) AU2009235931B2 (enExample)
CA (1) CA2720616C (enExample)
DK (1) DK2274005T3 (enExample)
ES (1) ES2425308T3 (enExample)
NZ (1) NZ588435A (enExample)
PL (1) PL2274005T3 (enExample)
PT (1) PT2274005E (enExample)
WO (1) WO2009124330A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
PL2859343T3 (pl) * 2012-06-06 2020-05-18 Attoquant Diagnostics Gmbh Sposób pomiaru peptydowych produktów degradacji kaskady proteolitycznej w próbkach krwi
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
EP2943216B1 (en) * 2013-01-14 2019-05-01 Apeiron Biologics AG Modified ace2 polypeptides
US9839668B2 (en) * 2013-12-11 2017-12-12 Attoquant Diagnostics Gmbh Compositions and methods for the treatment of diseases related to the renin-angiotensin-system
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US20200188473A1 (en) * 2017-05-02 2020-06-18 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
US11337909B2 (en) 2017-11-29 2022-05-24 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021202912A1 (en) * 2020-04-01 2021-10-07 Washington University Compositions for treatment of viral respiratory infections and methods of use thereof
CN112626099A (zh) * 2020-09-29 2021-04-09 清华大学 使用原核细胞发酵表达血管紧张素转化酶2的方法
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
US20250009853A1 (en) 2021-12-03 2025-01-09 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989363B1 (en) 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6610497B1 (en) 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US7375073B2 (en) * 2002-02-27 2008-05-20 Wake Forest University Health Sciences Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
ES2318137T3 (es) 2002-06-19 2009-05-01 University Health Network Activacion de ace2 para el tratamiento de enfermedades cardiacas, pulmonares y renales e hipertension.
EP1374907A3 (en) 2002-06-24 2004-01-07 Ghanem Elias c/o Institut Jules Bordet Ghanem Drug transport and delivery system
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid

Also Published As

Publication number Publication date
AT506632A1 (de) 2009-10-15
WO2009124330A2 (de) 2009-10-15
EP2644203A1 (de) 2013-10-02
CA2720616C (en) 2016-08-09
EP2274005A2 (de) 2011-01-19
US20110033524A1 (en) 2011-02-10
WO2009124330A3 (de) 2009-12-10
JP2011516501A (ja) 2011-05-26
US8946162B2 (en) 2015-02-03
EP2274005B1 (de) 2013-05-29
AU2009235931B2 (en) 2015-07-23
PL2274005T3 (pl) 2013-12-31
JP5650639B2 (ja) 2015-01-07
DK2274005T3 (da) 2013-08-19
AU2009235931A1 (en) 2009-10-15
CA2720616A1 (en) 2009-10-15
ES2425308T3 (es) 2013-10-14
PT2274005E (pt) 2013-08-27

Similar Documents

Publication Publication Date Title
NZ588435A (en) Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
GB2471588A (en) Therapeutic peptidomimetic macrocycles
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MX2020009811A (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico.
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
UA98629C2 (ru) Соединения и способ модуляции киназ
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
TW200744642A (en) Novel peptides for use in the treatment of obesity
NZ605871A (en) Treatment of sanfilippo syndrome type b
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
NZ601677A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
EP2521592A4 (en) INTENSITY-MODULATED ROTATION THERAPY WITH CONTINUOUS BED ROTATION / SHIFTING AND SIMULTANEOUS 3D IMAGING
NZ603717A (en) Suture line administration technique using botulinum toxins
NZ608734A (en) Bone marrow derived cd271 precursor cells for cardiac repair
NZ595143A (en) Treatment regimen utilizing neratinib for breast cancer
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
MX2014004994A (es) Cisteamina en el tratamiento de enfermedad fibrotica.
NZ609594A (en) Eph receptor expression in tumor stem cells
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
NZ590515A (en) Therapeutic use of specific ligand in msrv associated diseases
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
WO2008134752A3 (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 APR 2016 BY HENRY HUGHES

Effective date: 20130221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 APR 2019 BY THOMSON REUTERS

Effective date: 20130514

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2020 BY THOMSON REUTERS

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2021 BY PAVIS GMBH

Effective date: 20200331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2022 BY PAVIS PAYMENTS GMBH

Effective date: 20210326

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2023 BY PAVIS PAYMENTS GMBH

Effective date: 20220329

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20230325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2025 BY PAVIS PAYMENT GMBH

Effective date: 20240322

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2026 BY PAVIS PAYMENT GMBH

Effective date: 20250328